The original use of raloxifene 60 mg tablet was as a medication for the prevention and treatment of osteoporosis in postmenopausal women. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators (SERMs), which mimic the effects of estrogen in some tissues while blocking it in others. By selectively targeting estrogen receptors, raloxifene helps to maintain bone density and reduce the risk of fractures in women with osteoporosis, without the associated risks of hormone replacement therapy.
-
Reduction of Breast Cancer Risk: In addition to its effects on bone health, raloxifene has been shown to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for breast cancer. Clinical trials have demonstrated a significant reduction in the incidence of invasive breast cancer with raloxifene treatment, making it an important option for breast cancer prevention in certain populations.
-
Selective Estrogen Receptor Modulation: Raloxifene selectively modulates estrogen receptors in different tissues, acting as an estrogen agonist in bone and lipid metabolism but as an estrogen antagonist in breast and uterine tissues. This selective action allows raloxifene to provide beneficial effects on bone density and cardiovascular health while minimizing the risks of estrogen-related side effects such as breast cancer and uterine hyperplasia.
Raloxifene was first made as a drug to treat and avoid osteoporosis in women who have gone through menopause. It helps build stronger bones and lowers the risk of breaking them by acting on bone tissue like estrogen does.
